BACKGROUND: Translocated in liposarcoma-CCAAT/enhancer binding protein homologous protein (TLS-CHOP) (also known as FUS-DDIT3) chimeric oncoprotein is found in the majority of human myxoid liposarcoma (MLS), but its molecular function remains unclear. METHODS: We knockdowned TLS-CHOP expression in MLS-derived cell lines by a specific small interfering RNA, and analysed the gene expression profiles with microarray. RESULTS: TLS-CHOP knockdown inhibited growth of MLS cells, and induced an anticancer cytokine, melanoma differentiationassociated gene 7 (MDA-7)/interleukin-24 (IL-24) expression. However, double knockdown of TLS-CHOP and MDA-7/IL-24 did not inhibit MLS cell growth. CONCLUSION: Repression of MDA-7/IL-24 expression by TLS-CHOP is required for MLS tumour growth, and TLS-CHOP may become a promising therapeutic target for MLS treatment.
More than 90% of human myxoid liposarcoma (MLS) cases are associated with the chromosomal translocation, which creates a chimeric oncogene comprising part of the TLS (translocated in liposarcoma) gene (also known as FUS (fused in Ewing's sarcoma)) and part of the CHOP (CCAAT/enhancer binding protein (C/EBP) homologous protein) gene (also called DDIT3 (DNA damage-inducible transcript 3) and GADD153 (growth arrest-and DNA damage-inducible gene 153)) (Crozat et al, 1993; Rabbitts et al, 1993; Powers et al, 2010) . The resultant fusion gene TLS-CHOP encodes the N-terminal half of TLS fused to complete sequence of CHOP (Powers et al, 2010 ; Figure 1A ). TLS-CHOP protein is considered to function as an abnormal transcription factor (Kuroda et al, 1999; Pérez-Mancera et al, 2008; Andersson et al, 2010) . The definitive TLS-CHOP function for MLS development, however, is unclear.
Melanoma differentiation-associated gene 7 (MDA-7)/interleukin-24 (IL-24) protein is expressed in cells of the immune system and normal human melanocytes (Jiang et al, 1995; Wolk et al, 2002) . Exogenous expression of MDA-7/IL-24 induces growth arrest and apoptotic cell death in various human malignant cells Rahmani et al, 2010) .
In this report, we have found a novel pathway of TLS-CHOP with MDA-7/IL-24 repression.
MATERIALS AND METHODS

Cell culture
The MLS-derived cell lines, 1955/91 and 2645/94, were kindly provided from Professor David Ron (University of Cambridge), and were cultured in Dulbecco's modified Eagle's medium (SigmaAldrich Corporation, St Louis, MO, USA) supplemented with 10% foetal bovine serum. Cell quantification was performed as previously described (Oikawa et al, 2004) .
Small interfering RNA transfection
Small interfering RNA (siRNA) transfection (1 mM final concentration) was performed as previously described (Oikawa et al, 2004) . The nucleotide sequences of the chemically synthesised doublestranded siRNAs are as follows: TLS-CHOP siRNA, 5 0 -GGAAGUG UAUCUUCAUACAdTdT-3 0 ; MDA-7/IL-24 siRNA, 5 0 -GUGGAUGG GUGCUUAGUAAdTdT-3 0 ; and negative control siRNA, 5 0 -AUCC GCGCGAUAGUACGUAdTdT-3 0 .
Detection of TLS-CHOP variants and quantitative realtime PCR analysis
RNA isolation and first-strand cDNA synthesis were performed as previously described (Oikawa et al, 2008a) . For detection of TLS-CHOP variants, we performed PCR analysis with TLS-CHOP detection primers 5 0 -CTTATGGCCAGAGCCAGA AC-3 0 and 5 0 -AAGGCAATGACTCAGCTGCC-3 0 . The amplification products were sequenced with ABI PRISM 310 Genetic analyser (Applied Biosystems, Foster City, CA, USA). Real-time PCR analysis was performed as previously described (Oikawa et al, 2008b) using TLS-CHOP-specific primers 5 0 -ATGAACGGCTC AAGCAGGAA-3 0 and 5 0 -TGGTGCAGATTCACCATTCG-3 0 , and MDA-7/IL-24-specific primers 5 0 -GTTTTCCATCAGAGACAGTG-3 0 and 5 0 -GTAGAATTTCTGCATCCAGG-3 0 . The TLS-CHOP and MDA-7/IL-24 mRNA levels were normalised to b-actin signals (Oikawa et al, 2004) . We performed real-time PCR analysis in duplicate.
Microarray analysis
Cells were transfected with the TLS-CHOP or negative control siRNAs, and were incubated for 72 h. Biotin-labelled complementary RNA (cRNA) was then generated from 1 mg of total RNA of the cells using CodeLink iExpress Expression Assay Reagent Kit (GE Healthcare UK Ltd, Buckinghamshire, UK), and was hybridised to CodeLink Human Whole Genome Bioarray (GE Healthcare) using iAmplify cRNA Preparation and Hybridisation Reagents Kit (GE Healthcare) according to Expression Bioarray System User Guide ver. 2.0. The array slides were incubated for 21 h at 37 1C with shaking, and were scanned with a DNA microarray scanner G2505A (Agilent Technologies, Inc., Santa Clara, CA, USA). The scanned images were analysed and median normalised using CodeLink Expression Analysis Version 4.1.0.29054 (GE Healthcare). The data have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE33616.
Western blot analysis
Western blot analysis was performed as previously described (Oikawa et al, 2002) . Anti-TLS-CHOP monoclonal antibody (clone 14) was previously generated (Oikawa et al, 2006) . Monoclonal anti-a-tubulin antibody clone B-5-1-2 (T-5168; Sigma) was purchased. 
Plasmid construction and transfection
To create an MDA-7/IL-24 expression vector, cDNA fragment containing the complete coding region of MDA-7/IL-24 was amplified by PCR using the primers 5 0 -GCGCGGATCCGAGATGAATTTTCAA CAGAG-3 0 and 5 0 -GGCCAAGCTTCCTGGTCTAGACATTCAGAG-3 0 , and inserted into the mammalian expression vector, pcDNA3.1( À ) (Invitrogen, Carlsbad, CA, USA). Plasmid transfection was performed using Lipofectamine 2000 reagent (Invitrogen) and Opti-MEM I Reduced-Serum Medium (Invitrogen).
RESULTS
TLS-CHOP knockdown represses cell growth of MLS-derived cell lines
First, we examined the activity of the three newly designed effective siRNAs that target different positions of TLS-CHOP in a preliminary experiment (Supplementary Figure 1) , and selected the most effective siRNA among them (hereafter termed TLS-CHOP siRNA) for use in subsequent experiments. The TLS-CHOP Only the probes showing over twofold change in both two cell lines are listed. 'NULL' in Gene symbol column means that the probe sequence is not entried in NCBI database. siRNA targets exon 2 of the CHOP gene ( Figure 1A) . Although types 4 and 11 of TLS-CHOP variants do not have the target region, TLS-CHOP in over 80% of MLS is type 1 or 2. We confirmed that the two MLS-derived cell lines, 1955/91 and 2645/ 94, carries type 1 and type 2, respectively ( Figure 1B) . TLS-CHOP knockdown by the siRNA inhibited cell growth and induced cell death in both cell lines ( Figure 1C-F) . On the other hand, a nontargeting negative control siRNA did not affect cell growth, indicating that the effects of TLS-CHOP siRNA are not by offtarget effects.
TLS-CHOP knockdown induces MDA-7/IL-24 expression in MLS cells
Next, we compared mRNA expression profiles of both 1955/91 and 2645/94 cells transfected with TLS-CHOP siRNA or negative control siRNA by microarray analysis (see Materials and Methods). We found that several dozen genes showed at least two-fold differential expression by TLS-CHOP siRNA (Table 1) . Among the genes, we focused on the MDA-7/IL-24 gene because it encodes an anticancer cytokine . TLS-CHOP siRNA induced a significant increase in the expression of MDA-7/IL-24 in both cell lines (Table 1; Figure 2B ). Thus, to confirm that MDA-7/IL-24 is important for growth arrest by TLS-CHOP knockdown, we prepared MDA-7/IL-24 siRNA and performed double transfection with both TLS-CHOP and MDA-7/IL-24 siRNAs into 1955/91 cells. MDA-7/IL-24 knockdown cancelled the growth inhibitory effects by TLS-CHOP siRNA alone (Figure 2A and B).
Overexpression of MDA-7/IL-24 represses MLS cell growth
MDA-7/IL-24 displays nearly ubiquitous cancer-specific toxicity Rahmani et al, 2010) . To confirm that MDA-7/ IL-24 is also toxic for MLS, we transfected 1955/91 and 2645/94 cells with an MDA-7/IL-24 expression vector MDA-7/IL-24-pcDNA3.1( À ) or a control vector pcDNA3.1( À ). As shown in Figure 2C , MDA-7/IL-24-pcDNA(3.1) transfection represses the growth of the cells.
DISCUSSION
We have demonstrated that TLS-CHOP knockdown in MLS cells represses cell growth ( Figure 1C-E) , suggesting that TLS-CHOP plays an essential role for growth of MLS cells. Furthermore, our results suggest that TLS-CHOP may become a promising molecular target for MLS treatment.
TLS-CHOP knockdown in MLS cells induced increased expression of an anticancer cytokine MDA-7/IL-24 (Table 1; Figure 2B ). Thus, we consider that although the cancerous characteristics of MLS cells have potential to induce MDA-7/IL-24 expression, TLS-CHOP represses it and contributes to maintain the tumour growth.
In conclusion, we have revealed a novel pathway involving repression of MDA-7/IL-24 expression for tumourigenesis and/or growth of MLS. We believe that our results will contribute understanding of molecular function of the chimeric oncoprotein and development of a novel molecular therapy for cancers.
